The marketing authorisation for BindRen has been withdrawn at the request of the marketing authorisation holder.
BindRen : EPAR - Summary for the public (PDF/541.48 KB)
First published: 21/02/2013
Last updated: 01/04/2015
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Mitsubishi Pharma Europe Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
69 Old Broad Street
London EC2M 1QS
26/03/2015 BindRen - EMEA/H/C/002377 - IAIN/0004
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.